The clinical and regulatory catalysts (IND clearances, arbitration win, RMAT designation) significantly de-risk the pipeline and extend the value creation timeline into 2027. Traders should monitor study startup activities for PM577a and the upcoming IND/CTA submission for PM647 in Q3 2026 as the next key milestones.
Price Chart
Executive Summary
Prime Medicine reported Q2 2026 EPS of -$0.24, beating consensus of -$0.26 by 7.7%, with collaboration revenue of $1.154M roughly in line with the $1.1M estimate. The net loss narrowed to $42.1M from $52.6M a year ago, driven by lower R&D and G&A expenses. The stock is likely to move on the clinical and regulatory catalysts: IND/CTA clearances for PM577a in Wilson disease, a favorable arbitration resolution securing rights to PM647 in AATD, and FDA RMAT designation for PM359 in CGD, all of which de-risk the pipeline and extend the value creation narrative into 2027.
Key Financial Metrics
Key Facts
- EPS of -$0.24 beat consensus of -$0.26 (7.7% beat)
- Net loss narrowed to $42.1M from $52.6M YoY, a 19.9% improvement
- IND and CTA clearances for PM577a in Wilson disease establish a global Phase 1/2 program
- Favorable arbitration resolution with Beam Therapeutics secures Prime Medicine's rights to PM647 in AATD
- FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to PM359 in CGD
- Cash, cash equivalents, investments, and restricted cash of $108.8M as of June 30, 2026, providing runway into 2027
Financial Impact
Net loss improved by $10.5M YoY to $42.1M; cash burn of ~$42.6M in Q2 2026 vs ~$51.5M in Q2 2025
Risk Factors
- Cash runway only into 2027 — additional financing likely needed before clinical data readouts
- Clinical data from PM577a and PM647 not expected until 2027, leaving a long period with no catalysts
- Dilution risk from future equity offerings to fund operations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-053878 |
| Document: prme-20260806.htm | 0001628280-26-053878 |
| Document: 0001628280-26-053878-index-headers.html | 0001628280-26-053878 |
| Document: 0001628280-26-053878-index.html | 0001628280-26-053878 |
| Document: 0001628280-26-053878.txt | 0001628280-26-053878 |
| 8-K Data (Synthetic) | 0001628280-26-053878 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 24, 2026 4w ago | Press Release | $2.90 | awaiting T+60 | — | $3.67 (+26.55%) |
Aug 6, 2026 11w ago | 8-K | $2.95 | awaiting T+60 | — | $3.67 (+24.41%) |
Jul 8, 2026 15w ago | 8-K | $4.62 $3.06 | ▼ −33.87% | ▼ −36.19% | $3.67 (−20.56%) |
Jun 18, 2026 18w ago | Press Release | $3.23 $3.18 | ▼ −1.55% | ▼ −3.44% | $3.67 (+13.62%) |
May 7, 2026 24w ago | 8-K | $3.12 $2.81 | ▲ +9.79% | ▲ +13.62% | $3.67 (−17.82%) |
May 7, 2026 24w ago | Press Release | $3.12 $2.81 | ▲ +9.79% | ▲ +13.62% | $3.67 (−17.82%) |
Apr 16, 2026 27w ago | 8-K | $3.67 $3.52 | ▼ −4.22% | ▼ −11.27% | $3.67 (+0.00%) |
Mar 3, 2026 33w ago | Press Release | $4.23 $3.30 | ▼ −21.99% | ▼ −32.30% | $3.67 (−13.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers